SLATE-001 is under clinical development by Gritstone Bio and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SLATE-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SLATE-001 overview

SLATE-001 is under development for the treatment of solid tumors including non-small cell lung cancer, pancreatic ductal adenocarcinoma and metastatic colorectal cancer. It is administered through intramuscular route. It is a personalized tumor specific neoantigen candidate, comprises of fixed cassette of a chimpanzee adenovirus vector (ChAdV) and self-amplifying mRNA (SMA) boost. It is developed based on lipid nanoparticle (LNP) technology. It is developed based on EDGE antigen discovery platform.

Gritstone Bio overview

Gritstone Bio carries out the discovery, development, manufacture and deliver of the cancer and infectious disease immunotherapy candidates. The company product candidate comprises GRT-R910 (samRNA), GRT-C907(ChAd)/-R908 (samRNA), GRT- C909 (ChAd)/- R910(samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA). Its infectious diseases pipeline includes coral, a second-generation COVID-19 vaccine program and HIV therapeutic vaccine candidate. Gritstone Bio’s oncology programs comprise granite, an individualized neoantigen-based immunotherapy and slate, to treat non-small cell lung cancer. It also provides Gritstone edge an artificial intelligence and vaccine platforms to predict the tumor-specific neoantigens. The company also carries out the research and development activities and clinical trials. The company operate in Massachusetts and California, the US. Gritstone Bio is headquartered in Emeryville, California, the US.

For a complete picture of SLATE-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.